NMG
Nomenclature
NOD.Cg-PrkdcscidIl2rgem1Smoc
Cat. NO.
NM-NSG-001
Strain State
Repository Live
Gene Summary
Gene Symbol
IL2RG
Model Description
Validation Data
Figure 1. Complete deletion of T, B and NK cells in the spleen of NMG mice.(A) The splenocytes of BALB/c, NOD-scid and NMG mice were collected to analyze their compositions of T, B and NK cells by FACS. (B) Statistical analysis of sorted cells.
Figure 2. Complete deletion of T, B and NK cells in the blood of NMG mice.(A) The peripheral blood samples of BALB/c, NOD-scid and NMG mice were collected to analyze their compositions of T, B and NK cells by FACS.(B) Statistical analysis of sorted cells.
Figure 3. Compositions of monocytes, macrophages, DCs in the spleen of NMG mice. (A) The splenocytes of BALB/c, NOD-scid and NMG mice were collected to analyze their compositions of monocytes, macrophages, DCs. (B) Statistical analysis of sorted cells.
Figure 4. Compositions of monocytes, macrophages, DCs in the blood of NMG mice. (A) The peripheral blood samples of BALB/c, NOD-scid and NMG mice were collected to analyze their compositions of monocytes, macrophages, DCs. (B) Statistical analysis of sorted cells.
Figure 5. Histological sections of various tissues from NMG mice. Furthermore, no significant abnormalities were observed in other tissues, including brain, retina, spinal cord, heart, liver, lung, kidney, small intestine, large intestine, stomach, salivary glands, pancreas, ovary, uterus, testis, epididymis, skeletal muscle, skin, and brown fat.
Fig6.Serum antibody response in the serum of BALB/c, NOD-SCID, NMG and Blank. (n=5, 8-week-old, male)
Fig7. The establishment of tumor models using A549 or Raji cells is more effective in NMG mice.
A CDX model has been successfully established in NMG mice
Fig8. In vivo Efficacy Study of Anti-human CD47 Reference Antibody in the Treatment of Raji lymphoma CDX Tumor model in NMG mice.
Fig9. CAR-T in vivo efficacy study of A549 NSCLC model in NMG mice
Fig10. PBMC reconstitution model. Human PBMC cells were intravenous implanted into homozygote NMG mice. Percentage of human CD45+ cells (A), body weight (B).
Fig11. In vivo Efficacy Study of Hu-PBMC Reconstruction Model in NMG mice.
Fig12. Analysis of peripheral blood lymphocyte subpopulations of NMG mice after implantation of human CD34+ HSC at different times.
Fig13. Drug efficacy evaluation study performed in NMG mice reconstituted with hCD34+ cells. Humanized NMG mice reconstituted with human CD34+ cells were i.v. injected with MDA-MB-231 cells.
Fig14. Body weight growth curve of NMG.
Publications 59piece
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
